Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.51 |
| ▸ | ITGAV | P06756 | 16/20 | 0.51 |
| ▸ | ITGB5 | P18084 | 12/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.50 |
| ▸ | ITGA5 | P08648 | 5/20 | 0.50 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.50 |
| ▸ | ITGB6 | P18564 | 3/20 | 0.50 |
| ▸ | ITGB8 | P26012 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14585788 | 0.95 | ITGB3 (0.49) | ITGB3ITGAVITGB5ITGA2BITGA5 | |
| SCHEMBL17117494 | 0.94 | ITGB3 (0.51) | ITGB3ITGAVITGB5ITGA2BITGA5 | |
| SCHEMBL8364122 | 0.94 | ITGB3 (0.48) | ITGB3ITGAVITGB5ITGA2BITGA5 | |
| SCHEMBL8365134 | 0.90 | ITGB3 (0.48) | ITGB3ITGAVITGB5ITGA2BITGA5 | |
| SCHEMBL14585796 | 0.86 | ITGB3 (0.49) | ITGB3ITGAVITGB5ITGA2BITGA5 | |
| SCHEMBL8363710 | 0.85 | ITGB3 (0.45) | ITGB3ITGAVITGB5ITGA2BITGA5 | |
| SCHEMBL8365732 | 0.85 | ITGB3 (0.49) | ITGB3ITGAVITGB5ITGA2BITGA5 | |
| SCHEMBL14585789 | 0.84 | ITGB3 (0.47) | ITGB3ITGAVITGB5ITGA2BITGA5 | |
| SCHEMBL14585783 | 0.83 | ITGB3 (0.49) | ITGB3ITGAVITGB5ITGA2BITGA5 | |
| SCHEMBL20888358 | 0.82 | ITGB3 (0.58) | ITGB3ITGAVITGB5ITGA2BITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7179446-B2 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-02-20 | — | — | US | disclosed |
| US-6537520-B1 | Diagnosis and treatment of cancer; kit containing compound having peptide or peptidomimetic functionality that binds to a alpha v beta 3 receptor linked to a chelator | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-03-25 | — | — | US | disclosed |